Member Info for Mulder

.

Spin off news? Take over news? Market's bipolar and dementia nature lifting? Take your pick.

A profit is a profit at the end of the day. All those weeks stuck at 220p - makes you think about the rogueness of the market again doesn't it? Cast iron IMO Admittedly higher risk than Spire but you may want to look at Mothercare, Debenhams, Hikma, Sainsburys and Drax all of which I believe are grossly undervalued at the moment.

I guess there are a few day traders who got in at the bottom around 9 tempted to sell after such a small rise. I would say don't as the minimum SP this should be is around 1200p which it hit just a couple of weeks ago.

A deal must be stuck IMO for the reasons previously outlined. Soured relations and legal costs just two. Woodford needs this to happen badly also.

Looks like deadline may be extended beyond Monday.

Now above 200 day MA I believe.

Sorry substitute 'Debenhams' for 'this' The market is totally disregarding fundamentals with quite a few shares at the moment. Hikma also rose from 1120p to near 1200p only a couple of weeks ago pre-update. A 1% revision of the total revenue should not have resulted in a 25% drop!

Why is it that opening a short position automatically collapses an SP and then suppresses it, regardless of the fundamentals? Is this not blatant manipulation of a share price and therefore how can it still be allowed and be considered legal by the FCA?

By the way Fruitster do you know anyone in the FCA especially the market abuse department? Or have any contacts who work there? Why is it that opening a short position automa

It was only a month ago when this rose from 40p to 50p with shorts roughly the same as now. Recently both M&S and Pets At Home had shorts around 10% yet still rose from 310p-360p and 155p-210p respectively. Next is another. Home Retail Group/Argos had massive short interest yet was taken over by Sainsburys.

Just as a side note if you held through today you will also get 1.3p/share dividend. They are really dragging this out aren't they? Woodford has had a bad spell recently but surely he would not have increased his stake from 15% to 17% in this period unless there was a very strong chance of a 2nd offer and one that will be accepted. Otherwise makes no sense to be buying around 300p.

Hikma has just over 5% of its stock out on loan (versus none disclosed for Shire) and this may be contributing to a negative bias in pricing. With 41.5% owned by the chairman/chief executive and a pharma-major (Boehringer), the market in Hikma is relatively tight, hence it only needs an element of short closing to spur upside.*** Takeover interest from 16.6% shareholder? Boehringer Ingelheim is one of the world's 20 largest pharma companies and can't be ignoring the drop in market value of its stake from �1.07 billion to �448 million. The stake came about two years ago as a result of Hikma buying Boehringer's US generics side, the sale enabling it to focus on research and new products while retaining exposure to a market then seen as offering growth amid an ageing population and increased acceptance of generics. But whether Boehringer would seek to turn that logic on its head and re-purchase (plus a lot more) seems less likely. The stake may also complicate third-party bids, although Hikma's strong cash flow profile could appeal to buyout financiers. So, a takeover is possible if market sentiment festers.

�5Bn? Current market cap around �2.3Bn Hikma Hikma Pharmaceuticals has plenty of attractions as a takeover target, not least its exposure to emerging markets. *While the boss of this family-controlled firm once said he wouldn�t consider selling until the company reached a market value of �5bn, Hikma did consider a sale of its injectables-drug division last year, after unsolicited approaches from US group Amgen and Swiss giant Novartis, so things may have changed. Clearly, Hikma is on the radar of some of the world�s biggest pharma players. However, the current hot link for a bid is from �11bn US firm Mylan. Acquisition-hungry Mylan has twice been knocked back by Swedish company Meda recently, and could now turn its attention to Hikma, whose shares are trading at �15.75. Applying the AstraZeneca earnings rating and premium to Hikma, in the same way I did for Shire, gives prices of �17.15 and �21.75 for Hikma. Looking at Mylan�s bid for Meda, it was reported the offer was worth 14x analysts� forecast earnings before interest, tax, depreciation and amortisation on an enterprise value basis. A bid for Hikma on a similar basis would imply a share price of around �18.

Got several responses in the past actually from a Virginia Spring head of IR. Those with large investments in Hikma e.g. Aamir and Jimbo should contact/call her. Senior management + Board need to feel the pressure. Share price, lack of director buys and sale of the generics business just 3 of the topics to discuss. Virginia Spring Investor Relations Manager Hikma Pharmaceuticals PLC 1 New Burlington Place London W1S 2HR T +44 (0)20 3892 4389 M +44(0)79 7367 9502 E virginia@hikma.uk.com

The company needs to focus on the branded and injectables side of the business which make up >70% of total sales. Generics is <1/3rd of the business and if a good offer came in I suggest they sell it. Meanwhile IR are not responding and the BOD are very quiet - seems suspiciously similar to Spire...

Clearly a deal is close for them to pull this event and results release IMO.

Results were due tomorrow but that has disappeared from their calendar. Either way they only have until Monday.

Not long to wait now. Very low volumes today so far. The hedge fund that was shorting this has seemingly closed their position which should be a good sign.

Now would be a good time for both.